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Abstract
Purpose To evaluate the role of post-surgical medical
treatment with GnRHa in patients with DIE (Deep Infil-
trating Endometriosis) that received complete or incom-
plete surgery laparoscopic excision.
Methods Hundred fifty-nine patients with deep infiltrat-
ing endometriosis of the cul-de-sac and of the rectovaginal
septum with pelvic pain undergoing laparoscopic surgery
in academic tertiary-care medical center. Eighty patients
underwent complete laparoscopic excision of DIE (Arm A)
while 79 patients underwent incomplete surgery (Arm B).
After surgery each surgical arm was randomized in two
groups: no treatment groups 1A [40 pts] and 1B [40 pts]
and GnRHa treatment for 6 months groups 2A [40 pts] and
2B [39 pts]. Pain recurrence and quality of life were
evaluated in follow-up of 12 months and compared
between groups.
Results No differences were observed between patient
groups 1A and 2A. Groups 1A, 2A and 2B obtained sig-
nificantly lower pain scores than those achieved by the
group 1B undergoing incomplete surgical treatment and no
post-surgical therapy. At 1-year follow-up patients treated
with en-block resection (Groups 1A and 2A) showed the
lowest pain scores and the highest quality of life in com-
parison with the other two groups (Group 1B and 2B).
Conclusion GnRHa administration is followed by a
temporary improvement of pain in patients with incomplete
surgical treatment. It seems that it has no role on post-
surgical pain when the surgeon is able to completely excise
DIE implants.
Keywords Incomplete surgery  Medical therapy 
Quality of life  Endometriosis  GnRHa  Recurrences
Introduction
Deep infiltrating endometriosis (DIE) is a form of endo-
metriosis in which the pathologic tissue can penetrate up to
5 mm under the surface of the affected structure [1]. DIE
can affect the retrocervical region, uterosacral ligament,
rectum, rectovaginal septum, vagina, urinary tract and
other extraperitoneal pelvic sites [2]. The incidence of DIE
is reported in 20 % of all cases of endometriosis. Dys-
menorrhea, deep dyspareunia, dyschezia and dysuria are
the most frequently reported symptoms but even psycho-
logical symptoms have been reported [3]. Pain can be
treated by excising deep nodules and ovarian cysts in
laparoscopy [4, 5]. Recently even single port laparoscopy
has been proposed for the treatment of ovarian and peri-
toneal endometriosis but it seems too complex for DIE
excision [6, 7]. In most cases, women with chronic pelvic
pain (CPP) thought to be due to endometriosis are initially
treated empirically with non-steroidal anti-inflammatory
drugs (NSAIDS) and oral contraceptives. If these medica-
tions do not resolve the pain, laparoscopy is usually per-
formed to determine a definitive diagnosis and possibly
obtain a complete excision of all endometriotic implants
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[4, 8, 9]. However, several times a complete excision of
infiltrating endometriosis is not performed. The reasons are
the difficulty in defining exactly the extent of the disease,
the ability of the surgeon and, sometimes, the lack of the
patient consent to a radical excision of all endometriotic
implants due to the fear of possible complications (intes-
tinal fistulae etc.) [10]. Moreover, many patients with
chronic pain and infertility demand to the surgeon the
excision of endometriotic implants to restore the repro-
ductive function and possibly improve simptomatology but
avoiding any risk of intestinal complications. In these
cases, the rate of pelvic pain recurrence is very high and the
request for medical therapy is frequent. GnRH agonist
(GnRHa) is widely used for the treatment of endometriosis.
It is clinically evident that GnRHa decreases the serum
estrogen level by suppressing pituitary gonadotropin
secretion and remarkably improves the subjective and
objective symptoms of endometriosis [9–11]. GnRHa has
been proposed as a postsurgical treatment to avoid recur-
rences after laparoscopic surgery. However, it is still not
clear if GnRHa administration after surgery could prevent
recurrences in patients with complete excision of endome-
triotic implants or it acts just in cases of incomplete surgery.
Parazzini et al. [12] reported that medical treatment with
400 lg/day nasal Naferelin for 3 months after surgery did
not markedly improve short-term pelvic pain prognosis.
Vercellini et al. [13] using survival analysis, reported that
time to symptom recurrence was significantly longer in the
GnRH analogue group. However, another study did not
support the routine postoperative use of a 3-month course
of GnRHa in women with symptomatic endometriosis
stage III–IV. In fact, a significant longer relief of pain
symptoms in women with symptomatic endometriosis
stage III–IV was not observed [15].
Aim of our study was to investigate if GnRHa post-
surgical treatment should be proposed to every patient with
DIE who undergoes a laparoscopic treatment or if patients
who receive an extensive excisional treatment do not need
it in terms of pain and quality of life.
Sample size calculation
In calculating the sample size required, the primary
assessment was the recurrence rates. A 31 % recurrence
rate after laparoscopic reductive surgery and post-surgical
treatment with a GnRH analogue has been reported (10).
We expected a decrease in recurrence rates after laparo-
scopic complete excisional surgery, conservative surgery
and postsurgical treatment with GnRHa. A difference of
25 % between the allocated treatments was considered
signicant. To have a 90 % chance of detecting such a
difference at an overall significance level of 5 %, 40
patients for each group were required.
Materials and methods
This randomized clinical trial compared the efficacy of
GnRHa with no treatment in women with deep infiltrating
endometriosis and chronic pain who underwent laparo-
scopic surgery with complete or incomplete excision of all
endometriotic infiltrating implants. The study was con-
ducted at the Department of Obstetrics and Gynecology of
the University of Cagliari, Italy after approval by our
institution’s ethics committee and institutional review
board.
The study population was selected from women with
endometriosis who attended the Chronic Pelvic Pain Clinic
of the our Department and were submitted to laparoscopy
between January 2006 and December 2011. As usual all
patients underwent a complete biochemical, ultrasono-
graphic and MRI evaluation to characterize the site of the
lesions and possible involvement of the bowel [16, 17]. All
patients performed a preoperative diagnostic hysteroscopy
[18, 19]. Deep infiltrating endometriosis (DIE) of the rec-
tovaginal septum was classified according to Enzian score
[20]. Pain was evaluated by using the modified Biberoglu
and Behrman symptom scale as previously described [21],
on which symptoms and signs are rated on a scale of 0 (no
discomfort) to 3 (severe symptoms) in each of five cate-
gories, namely, dysmenorrhea, dyspareunia, pelvic pain,
pelvic tenderness and indurations. Patients enrolled in this
trial were required to have symptoms with a total score of
at least 6 (of a possible 15), including a total of at least two
in the symptoms of dysmenorrhea, dyspareunia and pelvic
pain. As usual for the patients attending to our center,
quality of life and health-related satisfaction were assessed
with the Medical Outcomes Survey Short Form 36 (SF-36),
which is the most widely used generic instrument to
evaluate health-related quality of life [22].
All women were advised to use non-hormonal contra-
ception throughout the study.
In conclusion, the criteria for inclusion were: (a) that the
patients were of reproductive age and not [40 years old;
(b) that the women had a laparoscopic diagnosis of deep
infiltrating endometriosis with complete or incomplete
surgical treatment; and (c) patient symptoms score before
surgery was required to have a total score of at least 6 (of a
possible 15).
Exclusion criteria were previous medical or surgical
therapy for endometriosis, infiltration of the rectum[3 cm
and/or rectal stenosis (Enzian score E4c), the presence of
other disease that might cause pelvic pain and diagnosis of
liver, endocrine or neoplastic disease.
Hundred fifty-nine out of 240 patients with surgical
proven deep DIE of the rectovaginal septum entered the
study after their written informed consent. Patients enrolled
to this trial were divided in two arms (Arm A and Arm B).
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Arm A (80 pts.) included the patients in which a com-
plete excision of all endometriotic implant was achieved
during surgery.
Surgical technique for the ‘‘complete’’ resection
of the rectovaginalendometriotic lesions
Mechanical bowel preparation (low residue diet for 5 days
prior to hospitalization; Selg 1000 [Promefarm, Italy] the
day before surgery) and preoperative IV antibiotics were
routine. Patients were counseled about the risks of entering
the rectum, with the associated risk of laparotomy or lap-
aroscopy with or without colostomy and gave their written
informed consent to the surgical treatment and the follow-
up evaluation. The goal of the operation was the radical
exeresis of all endometriotic lesions and in particular of all
fibrotic nodules of deep endometriosis, adhesions and all
ovarian and peritoneal lesions. After clinical examination
under general anesthesia, a uterine manipulator was posi-
tioned to displace the uterus anteriorly. A 10 mm trocar
was introduced through the umbilicus to position the lap-
aroscope (Karl Storz, Tuttlingen, Germany) and two 5 mm
trocars were placed in the lower abdomen and one of
10 mm on the sovrapubic area. A sponge-holding forceps
was inserted into the vagina to push up the posterior fornix
and another one was placed into the rectum. Using these
probes as guides the anterior rectum was separated from
the posterior vaginal wall using 5 mm monopolar electro-
surgical scissors, using preferentially sharp dissection
starting with the dissection of the pararectal spaces with
identification and lateralization of ureters in every case.
After identification of a cleavage plane between the
anterior rectal wall and the nodule, it was excised without
opening the rectal mucosa. In case of fibrosis of the sub-
mucosa, muscle layers were peeled with sharp dissection.
The mucosal skinning of the rectal wall was reinforced by
suturing the serous and muscularis mucosae in a single
layer with Vycril suture 3-0. Hemostasis was achieved with
bipolar electrodessication. All the recognizable lesions
were removed and submitted subsequently to histological
examination. The sponge holding forceps pushed in the
vagina enabled the presentation of the posterior vaginal
fornix that was opened and excised when involved by the
nodule. Antibiotic vaginal suppositories were placed into
the vagina very close to the suture for 7 days after opera-
tion to protect against ascending infections. In all cases, at
the end of the procedure 100 ml air was inflated into the
rectum to evidence any possible bowel lesion.
The Arm B (79 pts.) included the patients in whom
surgery did not allowed a complete removal of all infil-
trating implants for lack of patients consent to a radical
excision.
Surgical technique in the ‘‘incomplete’’ resection
of the rectovaginalendometriotic lesions
The preoperative preparation of patients was the same as in
Arm A. Adhesions, ovarian, peritoneal and uterosacral
ligaments endometriotic lesions were completely removed
in every patient but the deep infiltrating nodules were not
removed.
At the end of all laparoscopic procedures (‘‘complete’’
and ‘‘incomplete’’) to possibly prevent or decrease the
occurrence of post-surgical adhesions 500 cc of warm
lactated Ringer’s solution was instilled into the pelvis [23].
Randomization was achieved at the time of postopera-
tive control (12 days after surgery) so that a definitive
histological diagnosis of endometriosis was available.
In each arm the patients were randomized 1:1 in two
group (group 1A, 2A and 1B, 2B) in accordance with a
computer-generated randomization sequence to receive no
therapy or triptorelin acetate (Gonapeptyl depot, Ferring,
Italy) 3.75 mg given monthly by IM injection for
6 months. Patients were seen for a follow-up visit on a
monthly basis, at which time a pelvic examination was
performed. A patient diary, which included the endome-
triosis symptoms, was filled in by the patient every
3 months during 1-year period of the study. The SF36 was
fulfilled by the patients before surgery and at 1-year fol-
low-up.
Statistical methods
Data were analyzed with SPSS 10.1 (SPSS Inc, Chicago,
IL). Data analysis included age, previous pregnancies,
operative procedures, operating room time, intra and
postoperative complications, length of stay and 30-day
postoperative recovery. They were summarized as the
mean and standard deviation for continuous data and fre-
quency for categorical data. Within-group variations
between baseline and follow-up values were evaluated
using Wilcoxon matched pairs test. One-way repeated-
measured of variance (ANOVA) was used to compare the
results on the quality of life according to the SF36 results.
Significance level was accepted at p \ 0.05.
Results
The four groups of patients were similar with respect to
their demographic and clinical characteristics. There were
no significant differences with regard to age, fertility and
deep endometriosis scores according to Enzian classifica-
tion. No differences in baseline levels for pelvic pain were
found among the groups. (Table 1).
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All the procedures were completed laparoscopically
and no conversion to laparotomy was required. There
were two complications at surgery in Arm A. One
patient underwent rectal perforation and the rectum was
repaired by laparotomy. In another patient, the left ureter
was damaged during endometriosis excision and it was
repaired during laparoscopic surgery. The mean operat-
ing time was longer in the patients who underwent a
complete excision. The mean first operative day hemo-
globin drop and white blood cell (WBC) increased, the
need for analgesics and the hospital stay were not dif-
ferent in the two groups. We registered an intraoperative
surgical complication in the incomplete excision group.
During dissection, the ureter was cut and subsequently
repaired in laparoscopy without any problem for the
patient. All patients were fully recuperated in postoper-
ative day 30.
At 3 and 6 months follow-up, the 80 patients treated
with en-block resection of DIE (groups 1A and 2A) showed
the highest reduction of cumulative pain scores for chronic
pelvic pain, dysmenorrhea and dyspareunia. Moreover,
groups 1A and 2A did not present any significant differ-
ence at 3 and 6 months follow-up.
Moreover, pain control did not differ significantly
when these patients (groups 1A and 2A) were compared
with the 39 patients undergoing incomplete surgery and
post-surgical GnRHa treatment (Group 2B). Indeed,
groups 1A, 2A, 2B obtained significantly lower pain
scores than those achieved by the 40 patients (group 1B)
undergoing incomplete surgical treatment and no post-
surgical therapy (p \ 0.01). After discontinuation of
GnRHa and restoration of menstrual cycles, pain scores
returned to pre-surgical levels in patients undergoing
incomplete surgery and post-surgical medical treatment
(group 2B) and were significantly different in compari-
son of the patients (group 1A and 2A) who received a
complete excisional treatment (p \ 0.01). Data are
shown in Fig. 1.
Table 1 Characteristics of the
patients
Group 1A
(n = 40) complete
surgery no therapy
Group 2A (n = 40)
complete surgery
GnRH therapy
Group1B (n = 40)
incomplete surgery
no therapy
Group 2B (n = 39)
incomplete surgery
GnRH therapy
p
Age 24.2 ± 10 27.4 ± 8.2 25.6 ± 7.8 26.0 ± 10 NS
Enzian score
E1(a–c) 18 15 16 17 NS
E2(a–c) 10 11 9 9 NS
E3(a–c) 10 13 8 10 NS
E4(a–bb) 2 1 3 3 NS
Cumulative
pain
scores
11.3 ± 3 10.0 ± 1.9 10.4 ± 1.8 11.0 ± 2.1 NS
Infertility 13 10 10 12 NS
Fig. 1 Cumulative pain scores
in the randomized groups, *
p \ 0.01 vs. baseline, ?
p \ 0.001 vs. 6 months and
12 months in the incomplete
excision group without GnRHa
(group 1B) and vs. 12 months in
the incomplete treatment with
6 months administration
GnRHa (group 2B)
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Ten patients dropped out in the arm A (six patients in
group 1A and 4 in group 2A) because they got pregnant.
Six patients in the group 1B and 1 patient in group 2B
withdrew as they need hormonal treatment or repeated
surgery for important recurrence of pain.
Table 2 shows data regarding the patient satisfaction
with the treatments evaluated with the SF-36. This form
consists of eight domains (physical function, physical role
function, emotional role function, social function, general
health, mental health, vitality and pain). At 1-year follow-
up patients treated with en-block resection showed signif-
icant improvement in physical function (p \ 0.01), general
health (p \ 0.01) (Fig. 2), and vitality (p \ 0.01) in com-
parison to baseline and to 12 months follow-up of the
patients who underwent an incomplete surgical treatment.
Discussion
Endometriosis is a common, hormone-dependent gynae-
cological disease that is characterized by the presence and
growth of endometrial tissue outside the uterus and its
pathogenesis is still not clear [24, 25]. Deep infiltrating
endometriosis (DIE) frequently presents with pain and
dyspareunia. Preoperative vaginal and rectovaginal exam-
ination is essential to identify the presence of extensive
pelvic disease. Focal tenderness or nodularity of the cul-de-
sac and uterosacral ligaments is the best means of identi-
fying the disease that can be better characterized with
transvaginal ultrasound [26]. Many recent studies support
that complete excision of the endometriotic tissue provides
the best long-term results [4, 27, 28].
Table 2 Differences in the patients quality of life as assessed by SF-36 before surgery and at 12 months follow up
Group 1
baseline
Group 1
12 months
Group 2
baseline
Group 2A
12 months
Group 1B
baseline
Group 1B
12 months
Group 2B
baseline
Group 2B
12 months
General
health
46.4 ± 12 60 ± 11.5#? 48 ± 11.2 63.1 ± 13#? 45.4 ± 14 43.2 ± 11 44 ± 16 46 ± 18
Physical
function
51 ± 10 70 ± 12#? 53 ± 10.4 69 ± 11.1#? 48 ± 11 47 ± 14 53 ± 12 50 ± 10
Role
(physical)
57.2 ± 12 55.8 ± 10 54.8 ± 14 55.9 ± 16 59 ± 14 60 ± 16 55.8 ± 14 57.8 ± 16
Role
(emotional)
63 ± 10.8 62 ± 14 65.4 ± 15 64 ± 11.1 61 ± 12.8 60.2 ± 15 64 ± 14 62 ± 13.3
Mental
health
57.4 ± 14 55.1 ± 11,8 56 ± 12 58.5 ± 14 53.1 ± 11.8 53.5 ± 11.5 59.5 ± 11.5 60.9 ± 15
Social
function
55.8 ± 11 57.2 ± 14 56.2 ± 13 55.1 ± 15 57.8 ± 15 55 ± 15 59 ± 13 53.8 ± 14
Vitality 51.8 ± 13 65 ± 10#? 49.9 ± 11.3 68 ± 12#? 53 ± 10 53.1 ± 11 53.8 ± 12 52.1 ± 10
Pain 44.2 ± 13 68 ± 12#? 43,9 ± 11.4 67 ± 11#? 45.7 ± 16 45.1 ± 11.2 46.1 ± 15 42.1 ± 16
# p \ 0.001 vs. baseline, ? p \ 0.001 vs. 12 months incomplete excision and 12 months incomplete excision plus GnRHa
Fig. 2 Differences in the
patients general health, as
assessed by SF36, before
surgery and at 12 months follow
up, * p \ 0.001 vs. baseline and
vs. 12 months follow up in
patients with incomplete
excision with or without
6 months GnRHa
administration (group 1B and
2B)
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Since proper surgical management of the condition
requires complete excision of all the lesions, careful pal-
pation of any suspect lesion with a blunt probe to check for
possible infiltration and nodularity is essential. Retraction
of the rectosigmoid over the adenomyotic nodules in the
cul-de-sac frequently obscures disease and can result in
incomplete excision. The majority of patients with deep
endometriosis present endometriotic lesions in the retro-
cervical position and in the higher portion of the recto-
vaginal septum as shown by MRI images and this seems to
be the initial site of deep endometriotic invasion before
progression to rectovaginal septum and rectum [29].
Effective management of the advanced stages of the dis-
ease poses big problems, in particular, related to the
determination of the real extent of the infiltration, and
another important issue is the risk of possible complica-
tions. A radical approach appears difficult and the duration
of the operation is prolonged, but it can obtain the removal
of all endometriotic implants. Leaving these implants may
result in a high recurrence rate of pelvic symptoms. Our
study has clearly shown that patients who underwent an
incomplete excision present higher rates of pain recur-
rences and they need medical therapies and/or repeated
surgery. The early pain improvement in group 1B
(incomplete treatment) may be due to the removal of en-
dometriotic cyst, adhesions, peritoneal endometriotic
implants and nodules of the uterosacral ligaments, as well
as a placebo effect. Nevertheless, at 6 months after surgery
the pain relapsed if a complete excision had not been
performed or if the patients did not receive a medical post-
surgical treatment.
The surgical or medical approach to clinical recur-
rences is still a matter of debate. It is not still clear if a
medical treatment after surgery should be suggested to all
patients to avoid or at least delay such recurrences.
GnRHa is widely used in the treatment of endometriosis
symptoms. Several articles have been published reporting
the results of various trials comparing treatment of
endometriosis and its recurrences with GnRHa alone with
GnRHa plus add back therapy [30–32]. Following these
results many surgical units propose the adjuvant use of
GnRHa after surgery in all patients with deep endome-
triosis for at least 6 months. However, the long-term use
of GnRHa is associated with hypo estrogenic side effects
and a substantial reduction in bone mineral density [33].
In particular the administration of medical therapy after
surgery may have the detrimental effect to avoid the
possibility of spontaneous pregnancy.
The aim of our study was to evaluate if the patients in
whom a complete excisional treatment of all detectable
endometriosis nodule have any advantage of receiving a
post-surgical therapy with such drugs or the benefits are
limited to the patients with incomplete excisional
treatment. All the patients included presented severe
symptoms and confirmed deep infiltrating endometriosis at
surgery. Our results support that a postsurgical treatment
with GnRHa may be useful in reducing pain and in
delaying recurrences of symptoms in patients with
incomplete treatment. This is not a minor finding as many
patients with deep infiltrating endometriosis receive such a
surgery. In fact laparoscopy is widely diffuse in the
gynecological units and women with chronic pelvic pain
are promptly submitted to laparoscopy without referring to
specialized centers. The surgical treatment in these units is
limited to adhesiolysis and to the excision of endometrio-
mas in the deep infiltrating nodules without any treatment
or only partial resection. These patients can benefit of a
hormonal suppressing therapy to delay symptom recur-
rence. Unfortunately, our study has clearly shown that
symptom reappear as soon as there is the discontinuation of
the medical therapy. On the contrary, patients who receive
a complete surgical excision of deep endometriosis
implants do not need a postoperative administration of
GnRHa. The laparoscopic approach in patients with DIE is
often demanded not only to resolve pain, but also to obtain
pregnancies. It has been previously shown that surgical
treatment of DIE improves pregnancy rates [27, 28].
Consequently, in patients with reproductive desire the use
of GnRHa after complete excisional treatment of DIE may
not only be unnecessary, but also delay the possibility to
obtain a requested pregnancy.
The major limitation of this study was the short length
of follow-up (1 year). It is clear, that the rate of recur-
rence increased with an increase in the follow-up period.
It might be argued that increasing the follow-up period,
even the patients with complete excisional surgery but
without post-surgical medical treatment could develop
clinical recurrence. Moreover, our surgical approach to
the bowel involvement consisted in the shaving of all
visible lesions that could result in an incomplete excision
of microscopic implants which could increase recurrences
in the long-term follow-up in some patients [34]. It has
been clearly demonstrated that long-term administration
of estroprogestins markedly prevents endometriosis
recurrence [35]. Nevertheless, the medical treatment may
prevent pregnancy and our study clearly showed that in
the 1-year follow-up, patients extensively excised do not
need it.
In conclusion, complete surgical excision of deep
endometriosis improves the quality of life with a long-
lasting outcome. GnRHa administration is followed by a
temporary improvement of pain in patients with incomplete
surgical treatment, although, following discontinuation of
treatment, symptoms tend to recur. It seems that it has no
role when the surgeon is able to completely excise deep
endometriosis implants at least for one year.
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